Literature DB >> 20002560

Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.

J A Pineda1, J González, E Ortega, C Tural, J Macías, L Griffa, A Burgos.   

Abstract

Transient elastometry (TE) could provide a more accurate evaluation of the frequency and risk factors of liver fibrosis in hepatitis C virus (HCV) infection than that based on biopsy. The aim of this study was to assess the prevalence of and factors associated with significant liver fibrosis in a large population of HIV/HCV-coinfected patients. HIV/HCV-coinfected patients, who had participated in a cross-sectional, multicenter, retrospective study of liver fibrosis using noninvasive markers and in whom a determination of liver stiffness (LS) by TE was available, were included in this analysis. Factors potentially associated with significant fibrosis (LS ≥ 9 kPa) were analyzed. One thousand three hundred and ten patients fulfilled the inclusion criteria, 526 (40%) of them showed LS ≥ 9 kPa and 316 (24%) cirrhosis (LS ≥ 14 kPa). The factors independently associated with significant fibrosis [adjusted odds ratio (95% confidence interval, P value) were the following: older age [1.04 (1.01-1.07), 0.002], daily alcohol intake > 50 g/day [1.58 (1.10-2.27), 0.013] and the length of HCV infection [1.03 (1.00-1.06), 0.023]]. A CD4 cell count lower than < 200 per mm(3) [1.67 (0.99-2.81), 0.053] and HCV genotype 4 [0.66 (0.42-1.02), 0.066] were marginally associated with LS ≥ 9 kPa. In conclusion, the prevalence of cirrhosis in HIV/HCV-coinfected patients seems to be higher than previously reported in studies based on liver biopsy. Older age, alcohol consumption and lower CD4 cell counts are related with significant fibrosis. The latter association supports an earlier starting of antiretroviral therapy in this setting.
© 2009 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20002560     DOI: 10.1111/j.1365-2893.2009.01229.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  14 in total

1.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

2.  Transient micro-elastography: A novel non-invasive approach to measure liver stiffness in mice.

Authors:  Cécile Bastard; Matteo R Bosisio; Michèle Chabert; Athina D Kalopissis; Meriem Mahrouf-Yorgov; Hélène Gilgenkrantz; Sebastian Mueller; Laurent Sandrin
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

3.  The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals.

Authors:  H Nina Kim; Heidi M Crane; Carla V Rodriguez; Stephen Van Rompaey; Kenneth H Mayer; Katerina Christopoulos; Sonia Napravnik; Geetanjali Chander; Heidi Hutton; Mary E McCaul; Edward R Cachay; Michael J Mugavero; Richard Moore; Elvin Geng; Joseph J Eron; Michael S Saag; Joseph O Merrill; Mari M Kitahata
Journal:  AIDS Behav       Date:  2017-07

4.  Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.

Authors:  H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

5.  Current management of hepatitis C virus infection in patients with HIV co-infection.

Authors:  Mark S Sulkowski
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

6.  A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study.

Authors:  Laura Fernández-Sender; Carlos Alonso-Villaverde; Anna Rull; Esther Rodríguez-Gallego; Marta Riera-Borrull; Anna Hernández-Aguilera; Jordi Camps; Raúl Beltrán-Debón; Gerard Aragonès; Javier A Menendez; Jorge Joven
Journal:  AIDS Res Ther       Date:  2013-05-09       Impact factor: 2.250

7.  Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

Authors:  Johannes Vermehren; Annika Vermehren; Axel Mueller; Amina Carlebach; Thomas Lutz; Peter Gute; Gaby Knecht; Christoph Sarrazin; Mireen Friedrich-Rust; Nicole Forestier; Thierry Poynard; Stefan Zeuzem; Eva Herrmann; Wolf Peter Hofmann
Journal:  BMC Gastroenterol       Date:  2012-03-27       Impact factor: 3.067

Review 8.  Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?

Authors:  Athanasios-Dimitrios Bakasis; Theodoros Androutsakos
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

9.  Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment.

Authors:  Sang Hoon Han; Seung Up Kim; Chang Oh Kim; Su Jin Jeong; Jun Yong Park; Jun Yong Choi; Do Young Kim; Sang Hoon Ahn; Young Goo Song; Kwang-Hyub Han; June Myung Kim
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

10.  HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.

Authors:  Florence Abravanel; Stéphanie Raymond; Elodie Pambrun; Maria Winnock; Philippe Bonnard; Philippe Sogni; Pascale Trimoulet; François Dabis; Dominique Salmon-Ceron; Jacques Izopet
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.